Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell...

Ogkologos - 31 Ιανουαρίου, 2025

A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with...

Ogkologos - 29 Ιανουαρίου, 2025

Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors

Ogkologos - 28 Ιανουαρίου, 2025

Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic...

Ogkologos - 27 Ιανουαρίου, 2025

FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for...

Ogkologos - 24 Ιανουαρίου, 2025

EMA Recommends Extension of Indications for Dostarlimab

Ogkologos - 23 Ιανουαρίου, 2025

Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients...

Ogkologos - 22 Ιανουαρίου, 2025

Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab...

Ogkologos - 21 Ιανουαρίου, 2025

Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed...

Ogkologos - 20 Ιανουαρίου, 2025

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

Ogkologos - 17 Ιανουαρίου, 2025

1...596061...440 Σελίδα 60 από 440

MOST POPULAR

Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...

10 Απριλίου, 2024

Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells

14 Δεκεμβρίου, 2018

Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC...

29 Σεπτεμβρίου, 2023

Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With...

30 Μαΐου, 2022

Φόρτωση περισσοτέρων

FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell...

A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with...

Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors

Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic...

FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for...

EMA Recommends Extension of Indications for Dostarlimab

Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients...

Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab...

Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed...

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

MOST POPULAR

Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...

Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells

Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC...

Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With...

HOT NEWS

The incredible value of going public

Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer

Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients...

ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ